Global Primary Sclerosing Cholangitis (PSC) Market Research Report 2024(Status and Outlook)
Report Overview
This report provides a deep insight into the global Primary Sclerosing Cholangitis (PSC) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Primary Sclerosing Cholangitis (PSC) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Primary Sclerosing Cholangitis (PSC) market in any manner.
Global Primary Sclerosing Cholangitis (PSC) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan
Shire
Durect Corporation
Conatus Pharmaceuticals
Sirnaomics
Shenzhen HighTide Biopharmaceutical
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Market Segmentation (by Type)
Medical Treatement
Liver Transplantation
Others
Market Segmentation (by Application)
Hospital
Clinics
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Primary Sclerosing Cholangitis (PSC) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
This report provides a deep insight into the global Primary Sclerosing Cholangitis (PSC) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Primary Sclerosing Cholangitis (PSC) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Primary Sclerosing Cholangitis (PSC) market in any manner.
Global Primary Sclerosing Cholangitis (PSC) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan
Shire
Durect Corporation
Conatus Pharmaceuticals
Sirnaomics
Shenzhen HighTide Biopharmaceutical
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Market Segmentation (by Type)
Medical Treatement
Liver Transplantation
Others
Market Segmentation (by Application)
Hospital
Clinics
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Primary Sclerosing Cholangitis (PSC) Market
- Overview of the regional outlook of the Primary Sclerosing Cholangitis (PSC) Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Primary Sclerosing Cholangitis (PSC) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Primary Sclerosing Cholangitis (PSC)
1.2 Key Market Segments
1.2.1 Primary Sclerosing Cholangitis (PSC) Segment by Type
1.2.2 Primary Sclerosing Cholangitis (PSC) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Primary Sclerosing Cholangitis (PSC) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET COMPETITIVE LANDSCAPE
3.1 Global Primary Sclerosing Cholangitis (PSC) Sales by Manufacturers (2019-2024)
3.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Manufacturers (2019-2024)
3.3 Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Primary Sclerosing Cholangitis (PSC) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Primary Sclerosing Cholangitis (PSC) Sales Sites, Area Served, Product Type
3.6 Primary Sclerosing Cholangitis (PSC) Market Competitive Situation and Trends
3.6.1 Primary Sclerosing Cholangitis (PSC) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Primary Sclerosing Cholangitis (PSC) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PRIMARY SCLEROSING CHOLANGITIS (PSC) INDUSTRY CHAIN ANALYSIS
4.1 Primary Sclerosing Cholangitis (PSC) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Type (2019-2024)
6.3 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2019-2024)
6.4 Global Primary Sclerosing Cholangitis (PSC) Price by Type (2019-2024)
7 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Primary Sclerosing Cholangitis (PSC) Market Sales by Application (2019-2024)
7.3 Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) by Application (2019-2024)
7.4 Global Primary Sclerosing Cholangitis (PSC) Sales Growth Rate by Application (2019-2024)
8 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY REGION
8.1 Global Primary Sclerosing Cholangitis (PSC) Sales by Region
8.1.1 Global Primary Sclerosing Cholangitis (PSC) Sales by Region
8.1.2 Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region
8.2 North America
8.2.1 North America Primary Sclerosing Cholangitis (PSC) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Primary Sclerosing Cholangitis (PSC) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Primary Sclerosing Cholangitis (PSC) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Acorda Therapeutics
9.1.1 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Basic Information
9.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Overview
9.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.1.4 Acorda Therapeutics Business Overview
9.1.5 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) SWOT Analysis
9.1.6 Acorda Therapeutics Recent Developments
9.2 Gilead Sciences
9.2.1 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Basic Information
9.2.2 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Overview
9.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.2.4 Gilead Sciences Business Overview
9.2.5 Gilead Sciences Primary Sclerosing Cholangitis (PSC) SWOT Analysis
9.2.6 Gilead Sciences Recent Developments
9.3 NGM Biopharmaceuticals
9.3.1 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.3.4 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) SWOT Analysis
9.3.5 NGM Biopharmaceuticals Business Overview
9.3.6 NGM Biopharmaceuticals Recent Developments
9.4 Intercept Pharmaceuticals
9.4.1 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.4.4 Intercept Pharmaceuticals Business Overview
9.4.5 Intercept Pharmaceuticals Recent Developments
9.5 Dr. Falk Pharma
9.5.1 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
9.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
9.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.5.4 Dr. Falk Pharma Business Overview
9.5.5 Dr. Falk Pharma Recent Developments
9.6 Allergan
9.6.1 Allergan Primary Sclerosing Cholangitis (PSC) Basic Information
9.6.2 Allergan Primary Sclerosing Cholangitis (PSC) Product Overview
9.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.6.4 Allergan Business Overview
9.6.5 Allergan Recent Developments
9.7 Shire
9.7.1 Shire Primary Sclerosing Cholangitis (PSC) Basic Information
9.7.2 Shire Primary Sclerosing Cholangitis (PSC) Product Overview
9.7.3 Shire Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.7.4 Shire Business Overview
9.7.5 Shire Recent Developments
9.8 Durect Corporation
9.8.1 Durect Corporation Primary Sclerosing Cholangitis (PSC) Basic Information
9.8.2 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Overview
9.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.8.4 Durect Corporation Business Overview
9.8.5 Durect Corporation Recent Developments
9.9 Conatus Pharmaceuticals
9.9.1 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.9.4 Conatus Pharmaceuticals Business Overview
9.9.5 Conatus Pharmaceuticals Recent Developments
9.10 Sirnaomics
9.10.1 Sirnaomics Primary Sclerosing Cholangitis (PSC) Basic Information
9.10.2 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Overview
9.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.10.4 Sirnaomics Business Overview
9.10.5 Sirnaomics Recent Developments
9.11 Shenzhen HighTide Biopharmaceutical
9.11.1 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
9.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
9.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.11.4 Shenzhen HighTide Biopharmaceutical Business Overview
9.11.5 Shenzhen HighTide Biopharmaceutical Recent Developments
9.12 Glenmark
9.12.1 Glenmark Primary Sclerosing Cholangitis (PSC) Basic Information
9.12.2 Glenmark Primary Sclerosing Cholangitis (PSC) Product Overview
9.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.12.4 Glenmark Business Overview
9.12.5 Glenmark Recent Developments
9.13 Impax Laboratories
9.13.1 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Basic Information
9.13.2 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Overview
9.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.13.4 Impax Laboratories Business Overview
9.13.5 Impax Laboratories Recent Developments
9.14 Mylan
9.14.1 Mylan Primary Sclerosing Cholangitis (PSC) Basic Information
9.14.2 Mylan Primary Sclerosing Cholangitis (PSC) Product Overview
9.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.14.4 Mylan Business Overview
9.14.5 Mylan Recent Developments
9.15 Teva Pharmaceuticals
9.15.1 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.15.4 Teva Pharmaceuticals Business Overview
9.15.5 Teva Pharmaceuticals Recent Developments
9.16 Daewoong Pharmaceutical
9.16.1 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
9.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
9.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.16.4 Daewoong Pharmaceutical Business Overview
9.16.5 Daewoong Pharmaceutical Recent Developments
9.17 Mitsubishi Tanabe Pharma
9.17.1 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
9.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
9.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.17.4 Mitsubishi Tanabe Pharma Business Overview
9.17.5 Mitsubishi Tanabe Pharma Recent Developments
9.18 Lannett
9.18.1 Lannett Primary Sclerosing Cholangitis (PSC) Basic Information
9.18.2 Lannett Primary Sclerosing Cholangitis (PSC) Product Overview
9.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.18.4 Lannett Business Overview
9.18.5 Lannett Recent Developments
10 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET FORECAST BY REGION
10.1 Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast
10.2 Global Primary Sclerosing Cholangitis (PSC) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country
10.2.3 Asia Pacific Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region
10.2.4 South America Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Primary Sclerosing Cholangitis (PSC) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Primary Sclerosing Cholangitis (PSC) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Primary Sclerosing Cholangitis (PSC) by Type (2025-2030)
11.1.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Primary Sclerosing Cholangitis (PSC) by Type (2025-2030)
11.2 Global Primary Sclerosing Cholangitis (PSC) Market Forecast by Application (2025-2030)
11.2.1 Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) Forecast by Application
11.2.2 Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Primary Sclerosing Cholangitis (PSC)
1.2 Key Market Segments
1.2.1 Primary Sclerosing Cholangitis (PSC) Segment by Type
1.2.2 Primary Sclerosing Cholangitis (PSC) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Primary Sclerosing Cholangitis (PSC) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET COMPETITIVE LANDSCAPE
3.1 Global Primary Sclerosing Cholangitis (PSC) Sales by Manufacturers (2019-2024)
3.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Manufacturers (2019-2024)
3.3 Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Primary Sclerosing Cholangitis (PSC) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Primary Sclerosing Cholangitis (PSC) Sales Sites, Area Served, Product Type
3.6 Primary Sclerosing Cholangitis (PSC) Market Competitive Situation and Trends
3.6.1 Primary Sclerosing Cholangitis (PSC) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Primary Sclerosing Cholangitis (PSC) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PRIMARY SCLEROSING CHOLANGITIS (PSC) INDUSTRY CHAIN ANALYSIS
4.1 Primary Sclerosing Cholangitis (PSC) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Type (2019-2024)
6.3 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2019-2024)
6.4 Global Primary Sclerosing Cholangitis (PSC) Price by Type (2019-2024)
7 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Primary Sclerosing Cholangitis (PSC) Market Sales by Application (2019-2024)
7.3 Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) by Application (2019-2024)
7.4 Global Primary Sclerosing Cholangitis (PSC) Sales Growth Rate by Application (2019-2024)
8 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY REGION
8.1 Global Primary Sclerosing Cholangitis (PSC) Sales by Region
8.1.1 Global Primary Sclerosing Cholangitis (PSC) Sales by Region
8.1.2 Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region
8.2 North America
8.2.1 North America Primary Sclerosing Cholangitis (PSC) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Primary Sclerosing Cholangitis (PSC) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Primary Sclerosing Cholangitis (PSC) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Acorda Therapeutics
9.1.1 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Basic Information
9.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Overview
9.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.1.4 Acorda Therapeutics Business Overview
9.1.5 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) SWOT Analysis
9.1.6 Acorda Therapeutics Recent Developments
9.2 Gilead Sciences
9.2.1 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Basic Information
9.2.2 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Overview
9.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.2.4 Gilead Sciences Business Overview
9.2.5 Gilead Sciences Primary Sclerosing Cholangitis (PSC) SWOT Analysis
9.2.6 Gilead Sciences Recent Developments
9.3 NGM Biopharmaceuticals
9.3.1 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.3.4 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) SWOT Analysis
9.3.5 NGM Biopharmaceuticals Business Overview
9.3.6 NGM Biopharmaceuticals Recent Developments
9.4 Intercept Pharmaceuticals
9.4.1 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.4.4 Intercept Pharmaceuticals Business Overview
9.4.5 Intercept Pharmaceuticals Recent Developments
9.5 Dr. Falk Pharma
9.5.1 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
9.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
9.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.5.4 Dr. Falk Pharma Business Overview
9.5.5 Dr. Falk Pharma Recent Developments
9.6 Allergan
9.6.1 Allergan Primary Sclerosing Cholangitis (PSC) Basic Information
9.6.2 Allergan Primary Sclerosing Cholangitis (PSC) Product Overview
9.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.6.4 Allergan Business Overview
9.6.5 Allergan Recent Developments
9.7 Shire
9.7.1 Shire Primary Sclerosing Cholangitis (PSC) Basic Information
9.7.2 Shire Primary Sclerosing Cholangitis (PSC) Product Overview
9.7.3 Shire Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.7.4 Shire Business Overview
9.7.5 Shire Recent Developments
9.8 Durect Corporation
9.8.1 Durect Corporation Primary Sclerosing Cholangitis (PSC) Basic Information
9.8.2 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Overview
9.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.8.4 Durect Corporation Business Overview
9.8.5 Durect Corporation Recent Developments
9.9 Conatus Pharmaceuticals
9.9.1 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.9.4 Conatus Pharmaceuticals Business Overview
9.9.5 Conatus Pharmaceuticals Recent Developments
9.10 Sirnaomics
9.10.1 Sirnaomics Primary Sclerosing Cholangitis (PSC) Basic Information
9.10.2 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Overview
9.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.10.4 Sirnaomics Business Overview
9.10.5 Sirnaomics Recent Developments
9.11 Shenzhen HighTide Biopharmaceutical
9.11.1 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
9.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
9.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.11.4 Shenzhen HighTide Biopharmaceutical Business Overview
9.11.5 Shenzhen HighTide Biopharmaceutical Recent Developments
9.12 Glenmark
9.12.1 Glenmark Primary Sclerosing Cholangitis (PSC) Basic Information
9.12.2 Glenmark Primary Sclerosing Cholangitis (PSC) Product Overview
9.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.12.4 Glenmark Business Overview
9.12.5 Glenmark Recent Developments
9.13 Impax Laboratories
9.13.1 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Basic Information
9.13.2 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Overview
9.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.13.4 Impax Laboratories Business Overview
9.13.5 Impax Laboratories Recent Developments
9.14 Mylan
9.14.1 Mylan Primary Sclerosing Cholangitis (PSC) Basic Information
9.14.2 Mylan Primary Sclerosing Cholangitis (PSC) Product Overview
9.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.14.4 Mylan Business Overview
9.14.5 Mylan Recent Developments
9.15 Teva Pharmaceuticals
9.15.1 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
9.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
9.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.15.4 Teva Pharmaceuticals Business Overview
9.15.5 Teva Pharmaceuticals Recent Developments
9.16 Daewoong Pharmaceutical
9.16.1 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
9.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
9.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.16.4 Daewoong Pharmaceutical Business Overview
9.16.5 Daewoong Pharmaceutical Recent Developments
9.17 Mitsubishi Tanabe Pharma
9.17.1 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
9.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
9.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.17.4 Mitsubishi Tanabe Pharma Business Overview
9.17.5 Mitsubishi Tanabe Pharma Recent Developments
9.18 Lannett
9.18.1 Lannett Primary Sclerosing Cholangitis (PSC) Basic Information
9.18.2 Lannett Primary Sclerosing Cholangitis (PSC) Product Overview
9.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Product Market Performance
9.18.4 Lannett Business Overview
9.18.5 Lannett Recent Developments
10 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET FORECAST BY REGION
10.1 Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast
10.2 Global Primary Sclerosing Cholangitis (PSC) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country
10.2.3 Asia Pacific Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region
10.2.4 South America Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Primary Sclerosing Cholangitis (PSC) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Primary Sclerosing Cholangitis (PSC) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Primary Sclerosing Cholangitis (PSC) by Type (2025-2030)
11.1.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Primary Sclerosing Cholangitis (PSC) by Type (2025-2030)
11.2 Global Primary Sclerosing Cholangitis (PSC) Market Forecast by Application (2025-2030)
11.2.1 Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) Forecast by Application
11.2.2 Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Primary Sclerosing Cholangitis (PSC) Market Size Comparison by Region (M USD)
Table 5. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Primary Sclerosing Cholangitis (PSC) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Primary Sclerosing Cholangitis (PSC) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (PSC) as of 2022)
Table 10. Global Market Primary Sclerosing Cholangitis (PSC) Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Primary Sclerosing Cholangitis (PSC) Sales Sites and Area Served
Table 12. Manufacturers Primary Sclerosing Cholangitis (PSC) Product Type
Table 13. Global Primary Sclerosing Cholangitis (PSC) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Primary Sclerosing Cholangitis (PSC)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Primary Sclerosing Cholangitis (PSC) Market Challenges
Table 22. Global Primary Sclerosing Cholangitis (PSC) Sales by Type (K Units)
Table 23. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (M USD)
Table 24. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) by Type (2019-2024)
Table 25. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Type (2019-2024)
Table 26. Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) by Type (2019-2024)
Table 27. Global Primary Sclerosing Cholangitis (PSC) Market Size Share by Type (2019-2024)
Table 28. Global Primary Sclerosing Cholangitis (PSC) Price (USD/Unit) by Type (2019-2024)
Table 29. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) by Application
Table 30. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application
Table 31. Global Primary Sclerosing Cholangitis (PSC) Sales by Application (2019-2024) & (K Units)
Table 32. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Application (2019-2024)
Table 33. Global Primary Sclerosing Cholangitis (PSC) Sales by Application (2019-2024) & (M USD)
Table 34. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application (2019-2024)
Table 35. Global Primary Sclerosing Cholangitis (PSC) Sales Growth Rate by Application (2019-2024)
Table 36. Global Primary Sclerosing Cholangitis (PSC) Sales by Region (2019-2024) & (K Units)
Table 37. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region (2019-2024)
Table 38. North America Primary Sclerosing Cholangitis (PSC) Sales by Country (2019-2024) & (K Units)
Table 39. Europe Primary Sclerosing Cholangitis (PSC) Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales by Region (2019-2024) & (K Units)
Table 41. South America Primary Sclerosing Cholangitis (PSC) Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales by Region (2019-2024) & (K Units)
Table 43. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Basic Information
Table 44. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Overview
Table 45. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Acorda Therapeutics Business Overview
Table 47. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) SWOT Analysis
Table 48. Acorda Therapeutics Recent Developments
Table 49. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Basic Information
Table 50. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Overview
Table 51. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Gilead Sciences Business Overview
Table 53. Gilead Sciences Primary Sclerosing Cholangitis (PSC) SWOT Analysis
Table 54. Gilead Sciences Recent Developments
Table 55. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 56. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 57. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) SWOT Analysis
Table 59. NGM Biopharmaceuticals Business Overview
Table 60. NGM Biopharmaceuticals Recent Developments
Table 61. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 62. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 63. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Intercept Pharmaceuticals Business Overview
Table 65. Intercept Pharmaceuticals Recent Developments
Table 66. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
Table 67. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
Table 68. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Dr. Falk Pharma Business Overview
Table 70. Dr. Falk Pharma Recent Developments
Table 71. Allergan Primary Sclerosing Cholangitis (PSC) Basic Information
Table 72. Allergan Primary Sclerosing Cholangitis (PSC) Product Overview
Table 73. Allergan Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Allergan Business Overview
Table 75. Allergan Recent Developments
Table 76. Shire Primary Sclerosing Cholangitis (PSC) Basic Information
Table 77. Shire Primary Sclerosing Cholangitis (PSC) Product Overview
Table 78. Shire Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Shire Business Overview
Table 80. Shire Recent Developments
Table 81. Durect Corporation Primary Sclerosing Cholangitis (PSC) Basic Information
Table 82. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Overview
Table 83. Durect Corporation Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Durect Corporation Business Overview
Table 85. Durect Corporation Recent Developments
Table 86. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 87. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 88. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Conatus Pharmaceuticals Business Overview
Table 90. Conatus Pharmaceuticals Recent Developments
Table 91. Sirnaomics Primary Sclerosing Cholangitis (PSC) Basic Information
Table 92. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Overview
Table 93. Sirnaomics Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Sirnaomics Business Overview
Table 95. Sirnaomics Recent Developments
Table 96. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
Table 97. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
Table 98. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Shenzhen HighTide Biopharmaceutical Business Overview
Table 100. Shenzhen HighTide Biopharmaceutical Recent Developments
Table 101. Glenmark Primary Sclerosing Cholangitis (PSC) Basic Information
Table 102. Glenmark Primary Sclerosing Cholangitis (PSC) Product Overview
Table 103. Glenmark Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Glenmark Business Overview
Table 105. Glenmark Recent Developments
Table 106. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Basic Information
Table 107. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Overview
Table 108. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Impax Laboratories Business Overview
Table 110. Impax Laboratories Recent Developments
Table 111. Mylan Primary Sclerosing Cholangitis (PSC) Basic Information
Table 112. Mylan Primary Sclerosing Cholangitis (PSC) Product Overview
Table 113. Mylan Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Mylan Business Overview
Table 115. Mylan Recent Developments
Table 116. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 117. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 118. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Teva Pharmaceuticals Business Overview
Table 120. Teva Pharmaceuticals Recent Developments
Table 121. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
Table 122. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
Table 123. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Daewoong Pharmaceutical Business Overview
Table 125. Daewoong Pharmaceutical Recent Developments
Table 126. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
Table 127. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
Table 128. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Mitsubishi Tanabe Pharma Business Overview
Table 130. Mitsubishi Tanabe Pharma Recent Developments
Table 131. Lannett Primary Sclerosing Cholangitis (PSC) Basic Information
Table 132. Lannett Primary Sclerosing Cholangitis (PSC) Product Overview
Table 133. Lannett Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Lannett Business Overview
Table 135. Lannett Recent Developments
Table 136. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Region (2025-2030) & (K Units)
Table 137. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region (2025-2030) & (M USD)
Table 138. North America Primary Sclerosing Cholangitis (PSC) Sales Forecast by Country (2025-2030) & (K Units)
Table 139. North America Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 140. Europe Primary Sclerosing Cholangitis (PSC) Sales Forecast by Country (2025-2030) & (K Units)
Table 141. Europe Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 142. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales Forecast by Region (2025-2030) & (K Units)
Table 143. Asia Pacific Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region (2025-2030) & (M USD)
Table 144. South America Primary Sclerosing Cholangitis (PSC) Sales Forecast by Country (2025-2030) & (K Units)
Table 145. South America Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 146. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Consumption Forecast by Country (2025-2030) & (Units)
Table 147. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 148. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Type (2025-2030) & (K Units)
Table 149. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2025-2030) & (M USD)
Table 150. Global Primary Sclerosing Cholangitis (PSC) Price Forecast by Type (2025-2030) & (USD/Unit)
Table 151. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) Forecast by Application (2025-2030)
Table 152. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Primary Sclerosing Cholangitis (PSC) Market Size Comparison by Region (M USD)
Table 5. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Primary Sclerosing Cholangitis (PSC) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Primary Sclerosing Cholangitis (PSC) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (PSC) as of 2022)
Table 10. Global Market Primary Sclerosing Cholangitis (PSC) Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Primary Sclerosing Cholangitis (PSC) Sales Sites and Area Served
Table 12. Manufacturers Primary Sclerosing Cholangitis (PSC) Product Type
Table 13. Global Primary Sclerosing Cholangitis (PSC) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Primary Sclerosing Cholangitis (PSC)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Primary Sclerosing Cholangitis (PSC) Market Challenges
Table 22. Global Primary Sclerosing Cholangitis (PSC) Sales by Type (K Units)
Table 23. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (M USD)
Table 24. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) by Type (2019-2024)
Table 25. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Type (2019-2024)
Table 26. Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) by Type (2019-2024)
Table 27. Global Primary Sclerosing Cholangitis (PSC) Market Size Share by Type (2019-2024)
Table 28. Global Primary Sclerosing Cholangitis (PSC) Price (USD/Unit) by Type (2019-2024)
Table 29. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) by Application
Table 30. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application
Table 31. Global Primary Sclerosing Cholangitis (PSC) Sales by Application (2019-2024) & (K Units)
Table 32. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Application (2019-2024)
Table 33. Global Primary Sclerosing Cholangitis (PSC) Sales by Application (2019-2024) & (M USD)
Table 34. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application (2019-2024)
Table 35. Global Primary Sclerosing Cholangitis (PSC) Sales Growth Rate by Application (2019-2024)
Table 36. Global Primary Sclerosing Cholangitis (PSC) Sales by Region (2019-2024) & (K Units)
Table 37. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region (2019-2024)
Table 38. North America Primary Sclerosing Cholangitis (PSC) Sales by Country (2019-2024) & (K Units)
Table 39. Europe Primary Sclerosing Cholangitis (PSC) Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales by Region (2019-2024) & (K Units)
Table 41. South America Primary Sclerosing Cholangitis (PSC) Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales by Region (2019-2024) & (K Units)
Table 43. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Basic Information
Table 44. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Overview
Table 45. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Acorda Therapeutics Business Overview
Table 47. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) SWOT Analysis
Table 48. Acorda Therapeutics Recent Developments
Table 49. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Basic Information
Table 50. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Overview
Table 51. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Gilead Sciences Business Overview
Table 53. Gilead Sciences Primary Sclerosing Cholangitis (PSC) SWOT Analysis
Table 54. Gilead Sciences Recent Developments
Table 55. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 56. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 57. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) SWOT Analysis
Table 59. NGM Biopharmaceuticals Business Overview
Table 60. NGM Biopharmaceuticals Recent Developments
Table 61. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 62. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 63. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Intercept Pharmaceuticals Business Overview
Table 65. Intercept Pharmaceuticals Recent Developments
Table 66. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
Table 67. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
Table 68. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Dr. Falk Pharma Business Overview
Table 70. Dr. Falk Pharma Recent Developments
Table 71. Allergan Primary Sclerosing Cholangitis (PSC) Basic Information
Table 72. Allergan Primary Sclerosing Cholangitis (PSC) Product Overview
Table 73. Allergan Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Allergan Business Overview
Table 75. Allergan Recent Developments
Table 76. Shire Primary Sclerosing Cholangitis (PSC) Basic Information
Table 77. Shire Primary Sclerosing Cholangitis (PSC) Product Overview
Table 78. Shire Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Shire Business Overview
Table 80. Shire Recent Developments
Table 81. Durect Corporation Primary Sclerosing Cholangitis (PSC) Basic Information
Table 82. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Overview
Table 83. Durect Corporation Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Durect Corporation Business Overview
Table 85. Durect Corporation Recent Developments
Table 86. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 87. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 88. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Conatus Pharmaceuticals Business Overview
Table 90. Conatus Pharmaceuticals Recent Developments
Table 91. Sirnaomics Primary Sclerosing Cholangitis (PSC) Basic Information
Table 92. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Overview
Table 93. Sirnaomics Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Sirnaomics Business Overview
Table 95. Sirnaomics Recent Developments
Table 96. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
Table 97. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
Table 98. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Shenzhen HighTide Biopharmaceutical Business Overview
Table 100. Shenzhen HighTide Biopharmaceutical Recent Developments
Table 101. Glenmark Primary Sclerosing Cholangitis (PSC) Basic Information
Table 102. Glenmark Primary Sclerosing Cholangitis (PSC) Product Overview
Table 103. Glenmark Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Glenmark Business Overview
Table 105. Glenmark Recent Developments
Table 106. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Basic Information
Table 107. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Overview
Table 108. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Impax Laboratories Business Overview
Table 110. Impax Laboratories Recent Developments
Table 111. Mylan Primary Sclerosing Cholangitis (PSC) Basic Information
Table 112. Mylan Primary Sclerosing Cholangitis (PSC) Product Overview
Table 113. Mylan Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Mylan Business Overview
Table 115. Mylan Recent Developments
Table 116. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Basic Information
Table 117. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Overview
Table 118. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Teva Pharmaceuticals Business Overview
Table 120. Teva Pharmaceuticals Recent Developments
Table 121. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Basic Information
Table 122. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Overview
Table 123. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Daewoong Pharmaceutical Business Overview
Table 125. Daewoong Pharmaceutical Recent Developments
Table 126. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Basic Information
Table 127. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Overview
Table 128. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Mitsubishi Tanabe Pharma Business Overview
Table 130. Mitsubishi Tanabe Pharma Recent Developments
Table 131. Lannett Primary Sclerosing Cholangitis (PSC) Basic Information
Table 132. Lannett Primary Sclerosing Cholangitis (PSC) Product Overview
Table 133. Lannett Primary Sclerosing Cholangitis (PSC) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Lannett Business Overview
Table 135. Lannett Recent Developments
Table 136. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Region (2025-2030) & (K Units)
Table 137. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region (2025-2030) & (M USD)
Table 138. North America Primary Sclerosing Cholangitis (PSC) Sales Forecast by Country (2025-2030) & (K Units)
Table 139. North America Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 140. Europe Primary Sclerosing Cholangitis (PSC) Sales Forecast by Country (2025-2030) & (K Units)
Table 141. Europe Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 142. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales Forecast by Region (2025-2030) & (K Units)
Table 143. Asia Pacific Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region (2025-2030) & (M USD)
Table 144. South America Primary Sclerosing Cholangitis (PSC) Sales Forecast by Country (2025-2030) & (K Units)
Table 145. South America Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 146. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Consumption Forecast by Country (2025-2030) & (Units)
Table 147. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Country (2025-2030) & (M USD)
Table 148. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Type (2025-2030) & (K Units)
Table 149. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2025-2030) & (M USD)
Table 150. Global Primary Sclerosing Cholangitis (PSC) Price Forecast by Type (2025-2030) & (USD/Unit)
Table 151. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) Forecast by Application (2025-2030)
Table 152. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Primary Sclerosing Cholangitis (PSC)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD), 2019-2030
Figure 5. Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) (2019-2030)
Figure 6. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Primary Sclerosing Cholangitis (PSC) Market Size by Country (M USD)
Figure 11. Primary Sclerosing Cholangitis (PSC) Sales Share by Manufacturers in 2023
Figure 12. Global Primary Sclerosing Cholangitis (PSC) Revenue Share by Manufacturers in 2023
Figure 13. Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Primary Sclerosing Cholangitis (PSC) Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Primary Sclerosing Cholangitis (PSC) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Primary Sclerosing Cholangitis (PSC) Market Share by Type
Figure 18. Sales Market Share of Primary Sclerosing Cholangitis (PSC) by Type (2019-2024)
Figure 19. Sales Market Share of Primary Sclerosing Cholangitis (PSC) by Type in 2023
Figure 20. Market Size Share of Primary Sclerosing Cholangitis (PSC) by Type (2019-2024)
Figure 21. Market Size Market Share of Primary Sclerosing Cholangitis (PSC) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application
Figure 24. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Application (2019-2024)
Figure 25. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Application in 2023
Figure 26. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application (2019-2024)
Figure 27. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application in 2023
Figure 28. Global Primary Sclerosing Cholangitis (PSC) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region (2019-2024)
Figure 30. North America Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country in 2023
Figure 32. U.S. Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Primary Sclerosing Cholangitis (PSC) Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Primary Sclerosing Cholangitis (PSC) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country in 2023
Figure 37. Germany Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region in 2023
Figure 44. China Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (K Units)
Figure 50. South America Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country in 2023
Figure 51. Brazil Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Primary Sclerosing Cholangitis (PSC) Market Share Forecast by Type (2025-2030)
Figure 65. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Application (2025-2030)
Figure 66. Global Primary Sclerosing Cholangitis (PSC) Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Primary Sclerosing Cholangitis (PSC)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD), 2019-2030
Figure 5. Global Primary Sclerosing Cholangitis (PSC) Market Size (M USD) (2019-2030)
Figure 6. Global Primary Sclerosing Cholangitis (PSC) Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Primary Sclerosing Cholangitis (PSC) Market Size by Country (M USD)
Figure 11. Primary Sclerosing Cholangitis (PSC) Sales Share by Manufacturers in 2023
Figure 12. Global Primary Sclerosing Cholangitis (PSC) Revenue Share by Manufacturers in 2023
Figure 13. Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Primary Sclerosing Cholangitis (PSC) Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Primary Sclerosing Cholangitis (PSC) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Primary Sclerosing Cholangitis (PSC) Market Share by Type
Figure 18. Sales Market Share of Primary Sclerosing Cholangitis (PSC) by Type (2019-2024)
Figure 19. Sales Market Share of Primary Sclerosing Cholangitis (PSC) by Type in 2023
Figure 20. Market Size Share of Primary Sclerosing Cholangitis (PSC) by Type (2019-2024)
Figure 21. Market Size Market Share of Primary Sclerosing Cholangitis (PSC) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application
Figure 24. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Application (2019-2024)
Figure 25. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Application in 2023
Figure 26. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application (2019-2024)
Figure 27. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application in 2023
Figure 28. Global Primary Sclerosing Cholangitis (PSC) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region (2019-2024)
Figure 30. North America Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country in 2023
Figure 32. U.S. Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Primary Sclerosing Cholangitis (PSC) Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Primary Sclerosing Cholangitis (PSC) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country in 2023
Figure 37. Germany Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region in 2023
Figure 44. China Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (K Units)
Figure 50. South America Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country in 2023
Figure 51. Brazil Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Primary Sclerosing Cholangitis (PSC) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Primary Sclerosing Cholangitis (PSC) Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Primary Sclerosing Cholangitis (PSC) Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Primary Sclerosing Cholangitis (PSC) Market Share Forecast by Type (2025-2030)
Figure 65. Global Primary Sclerosing Cholangitis (PSC) Sales Forecast by Application (2025-2030)
Figure 66. Global Primary Sclerosing Cholangitis (PSC) Market Share Forecast by Application (2025-2030)
